This site is intended for health care professionals only.

ZELAPAR® (selegiline HCL) tolerability, treatment-emergent adverse events ZELAPAR® (selegiline HCL) tolerability, treatment-emergent adverse events

SAFETY

ZELAPAR tolerability

Treatment-emergent adverse events reported in >5% of ZELAPAR-treated patients1
All patients were on concomitant levodopa/carbidopa

Adverse event ZELAPAR (n=194) Placebo (n=98)
Nausea

11%

9%

Dizziness

11%

8%

Pain

8%

7%

Headache

7%

6%

Insomnia

7%

4%

Rhinitis

7%

6%

Dyskinesia

6%

3%

Skin disorders

6%

2%

Stomatitis

5%

4%

Back pain

5%

3%

Dyspepsia

5%

3%

Incidence of treatment-emergent adverse events reported in >5% of patients treated with ZELAPAR and more frequently with ZELAPAR than with placebo. Patients may have reported multiple adverse events during the study or at discontinuation and therefore may be included in more than one category. Please see full Prescribing Information for additional adverse events reported in <5% of patients.